B of A Securities upgraded Checkmate Pharmaceuticals from Neutral to Buy and set a new price target of $7.00

-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024 /PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an oversubscribed $115 million Series A financing. Proceeds from the financing will be used to advance Axonis' lead development candidate, AXN-027, through clinical proof-of-concept in patients. AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essent

- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and closing on approximately $528 million in capital commitments in an oversubscribed fundraise. The firm initiated the fundraise for Fund V in mid-April. Limited partners of Fund V include a broad range of institutional investors comprising sovereign wealth funds, corporate pensions, financial institutions, university endowments, medical institutions, foundations, family offices and funds-of-funds. Under the fund leadership of Managing Partners Richard Gaster, M.D., Ph.D., Corey Goo

CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced first quarter 2022 financial results and provided a business update. "We remain focused on the execution of the clinical program for vidutolimod and are delighted with the opportunity to become part of Regeneron, who will help to accelerate the development of vidutolimod as a potential novel treatment for multiple tumor types," said Alan Bash, President and Chief Executive Officer of Checkmate. "This is an excitin

Proposed ~$250 million all-cash acquisition strengthens Regeneron's portfolio of diverse and combinable immuno-oncology candidates Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses observed in PD-1 refractory melanoma as monotherapy Vidutolimod is currently being studied in combination with other agents for melanoma, non-melanoma skin cancers, and head and neck cancer TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) a clinical stage biopharmaceutical company focused on proprietary t

CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) ("Checkmate"), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the presentation of biomarker signature data from two studies evaluating vidutolimod, a first-in-class, immunostimulatory, noninfectious virus-like particle (VLP) containing a CpG-A Toll-like receptor 9 (TLR9) agonist. The first study evaluated vidutolimod in patients with advanced anti-PD-(L)1 refractory melanoma who received intratumoral vidutolimod monotherapy or in combination with intravenous pembrolizumab, and

Alan Bash, experienced biopharmaceutical executive, appointed President and CEO Clinical trials with vidutolimod (CMP-001) in melanoma, head and neck cancer indications ongoing; Trial dosing initiated in cohorts for PD-1 refractory non-melanoma skin cancers Preliminary clinical data readouts anticipated in second half of 2022 CAMBRIDGE, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced full year 2021 financial results and provided a business update. "Our vidutolimod p

CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) ("Checkmate"), a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that it will present biomarker data at the 2022 American Association for Cancer Research (AACR) Annual Meeting taking place in New Orleans, Louisiana from April 8-13, 2022. An e-poster will be made available online starting Friday, April 8 at 1:00pm ET. Poster Presentation Details:  Title: Novel transcriptional signatures associated with antitumor activity in vidutolimod (vidu)-treated patients (pts) with anti-PD-

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Alan Bash as President and Chief Executive Officer, effective March 1, 2022. Mr. Bash, who will also join the Board of Directors, will succeed Alan Fuhrman, who has served as interim President and Chief Executive Officer since October 2021. Mr. Fuhrman will continue to serve Checkmate as a member of the Board of Directors. "I am very pleased to welcome Alan Bash as President and CEO. With ove

CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the addition of Jon Wigginton, M.D. to its Board of Directors ("Board"). "Jon is a well-respected physician-scientist and drug development expert. With his diverse background, he has driven numerous clinical stage immuno-oncology development portfolios," said Alan Fuhrman, Interim CEO and President of Checkmate. "We are thrilled to strengthen Checkmate's Board by leveraging Jon's broad experience across academia,

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman, Interim CEO and President, will present at the H.C. Wainwright BioConnect Virtual Conference being held on January 10-13, 2022. The pre-recorded webcast will be available on-demand starting on Monday, January 10 at 7:00am ET. Checkmate will also host 1x1 investor meetings during the conference. About Checkmate Pharmaceuticals Checkmate Pharmaceuticals is a clinical stage biotechnology company

Kuros Biosciences AG ("Kuros" or the "Company"), a leader in next generation bone graft technologies, notes the completion of the acquisition of Checkmate Pharmaceuticals (NASDAQ:CMPI) by Regeneron Pharmaceuticals (NASDAQ:REGN). The completion triggers a $5 million milestone payment under a license agreement entered into by Kuros and Checkmate in 2015. Under a royalty purchase agreement entered into by Kuros and XOMA Corporation (NASDAQ:XOMA) in 2021, XOMA is entitled to receive 50% of the milestone payment paid to Kuros as a result of a change of control of Checkmate Pharmaceuticals. Therefore, $2.5 million of the $5 million milestone due to Kuros under the 2015 license agreement will be p

Checkmate Pharmaceuticals (NASDAQ:CMPI) reported quarterly losses of $(0.73) per share. This is a 12.31 percent decrease over losses of $(0.65) per share from the same period last year.

Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering rate hike fears. On the M&A front, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced a deal to buy Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) for $250 million. Johnson & Johnson, Inc. (NYSE:JNJ) kickstarted the pharma reporting season with mixed first-quarter results. The company withdrew its COVID-19 vaccine guidance for the year, citing global supply surplus and demand uncertainty. Here are the key catalysts for the unfolding week: Conferences 2022 American Society of Cataract

Upgrades For Avis Budget Group Inc (NASDAQ:CAR), Barclays upgraded the previous rating of Underweight to Equal-Weight. In the fourth quarter, Avis Budget Gr showed an EPS of $7.08, compared to $0.36 from the year-ago quarter. The stock has a 52-week-high of $545.11 and a 52-week-low of $65.87. At the end of the last trading period, Avis Budget Gr closed at $285.35. According to Needham, the prior rating for Netflix Inc (NASDAQ:NFLX) was changed from Underperform to Hold. For the first quarter, Netflix had an EPS of $3.53, compared to year-ago quarter EPS of $3.75. The stock has a 52-week-high of $700.99 and a 52-week-low of $329.82. At the end of the last trading period, Netflix closed at

BTIG analyst Kaveri Pohlman downgrades Checkmate Pharmaceuticals (NASDAQ:CMPI) from Buy to Neutral.

Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) shares jumped 325.9% to close at $10.35 on Tuesday after Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced a deal to acquire the company for $10.50 per share in cash. Sono Group N.V. (NASDAQ:SEV) climbed 65.2% to close at $7.60. Sharps Technology, Inc. (NASDAQ:STSS) shares gained 40.5% to close at $2.43 after dipping 18% on Monday. The company recently priced its IPO at $4.25 per share. ToughBuilt Industries, Inc. (NASDAQ:TBLT) gained 37% to close at $0.2010 as the company posted a narrower FY21 loss. Baosheng Media Group Holdings Limited (NASDAQ:BAOS) rose 33.3% to close at $0.78. Terran Orbital Corporation (NYSE:LLAP) gai

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Tuesday. The Dow traded up 1.08% to 34,783.91 while the NASDAQ rose 1.60% to 13,545.62. The S&P also rose, gaining, 1.17% to 4,442.95. Also check this: 4 Stocks Under $5 Insiders Are Aggressively Buying Leading and Lagging Sectors Consumer discretionary shares jumped by 2.2% on Tuesday. Meanwhile, top gainers in the sector included Sono Group N.V. (NASDAQ:SEV), up 72% and The RealReal, Inc. (NASDAQ:REAL) up 9%. In trading on Tuesday, energy shares fell 0.7%. Top Headline Johnson & Johnson (NYSE:JNJ) reported better-than-expected earnings for its first quarter, but sus

  Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) stock increased by 331.9% to $10.41 during Tuesday's regular session. Trading volume for Checkmate Pharmaceuticals's stock is 3.4 million as of 13:30 EST. This is 25265.9% of its average full-day volume over the last 100 days. The company's market cap stands at $225.1 million. Sharps Technology (NASDAQ:STSS) shares moved upwards by 45.06% to $2.51. Trading volume for this security as of 13:30 EST is 101.5 million, which is 4236.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $23.0 million. Axsome Therapeutics (NASDAQ:AXSM) stock rose 23.57% to $40.41. Trading volume for Axsome

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Tuesday. The Dow traded up 1.13% to 34,800.08 while the NASDAQ rose 1.82% to 13,575.33. The S&P also rose, gaining, 1.27% to 4,447.64. Also check this: 4 Stocks Under $5 Insiders Are Aggressively Buying Leading and Lagging Sectors Consumer discretionary shares jumped by 2.5% on Tuesday. Meanwhile, top gainers in the sector included Sono Group N.V. (NASDAQ:SEV), up 47% and (NASDAQ:HOUR) up 10%. In trading on Tuesday, energy shares fell 1.2%. Top Headline Johnson & Johnson (NYSE:JNJ) reported better-than-expected earnings for its first quarter, but suspended sales forecast

CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Alan Bash as President and Chief Executive Officer, effective March 1, 2022. Mr. Bash, who will also join the Board of Directors, will succeed Alan Fuhrman, who has served as interim President and Chief Executive Officer since October 2021. Mr. Fuhrman will continue to serve Checkmate as a member of the Board of Directors. "I am very pleased to welcome Alan Bash as President and CEO. With ove

CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) ("Checkmate"), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the addition of Joy Yan, M.D., Ph.D. to its Board of Directors ("Board"). "Joy's impressive track record in immuno-oncology focused clinical development will be valuable as we continue to advance vidutolimod toward registration in melanoma and proof of concept in additional indications," commented Alan Fuhrman, Interim CEO and President of Checkmate. "We are pleased to welcome Joy to Checkmate's Board." Dr. Yan

Robert F. Dolski appointed as Chief Financial Officer Katherine Eade appointed as General Counsel CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced the appointment of Robert F. Dolski as Chief Financial Officer. Mr. Dolski brings to Checkmate more than 20 years of diversified management experience as a life sciences financial executive driving the strategy, planning, execution, and financing of private and public biopharmaceutical companies. In addition to Mr

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

4 - Checkmate Pharmaceuticals, Inc. (0001651431) (Issuer)

SC 13G/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

SC 13D/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

SC 13D/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

SC 13D - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

SC 13D/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

SC 13G - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

SC 13G/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

SC 13D/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

SC 13G/A - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)

SC 13G - Checkmate Pharmaceuticals, Inc. (0001651431) (Subject)